Animal Study: Mitragynine's Addiction Profile and Cognitive Impairments Closely Mirror Morphine in Rodent Models

Why it matters

This is one of the most comprehensive preclinical studies of mitragynine's addiction and cognitive effects, and its finding that the profile "closely resembles morphine" has been cited repeatedly in scheduling arguments. The results are important — but come from animal models at laboratory doses, not from the range of doses used by human kratom consumers.

The big picture

Preclinical evidence of addiction potential and cognitive impairment has anchored regulatory arguments for restricting kratom. But translation from rodent models to human outcomes is uncertain — particularly given that kratom users typically consume the whole plant extract rather than isolated mitragynine at the doses used in this study.

Key findings

• • Mitragynine produced conditioned place preference (reward behavior) in rodents, resembling the reinforcement profile of morphine
• • Repeated mitragynine induced locomotor sensitization and enhanced dopamine transporter and receptor-regulating factor mRNA in the mesencephalon
• • Severe somatic withdrawal signs appeared after 12 hours of abstinence; anxiety emerged after 24 hours; hypersensitivity to small doses persisted for up to 14 days
• • Acute mitragynine impaired passive avoidance learning, memory consolidation and retrieval, and disrupted cortical oscillatory activity (suppressing delta and theta rhythms)
• • Chronic administration led to impaired object recognition learning — a form of cognitive impairment not seen with acute dosing

What they say

Rodent behavioral pharmacology study using Sprague-Dawley rats and mice; mitragynine isolated from Malaysian kratom leaves; Universiti Sains Malaysia, Friedrich-Alexander-University Erlangen-Nuremberg, Griffith University, and Queen's University; Addiction Biology, 2014.

Bottom line

Mitragynine's addiction and cognitive impairment profile in animal models is concerning — but direct translation to human health outcomes requires human studies at doses and formulations people actually use.